Amylyx Pharmaceuticals Q3 Earnings Call Highlights
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
Amylyx Pharmaceuticals (NASDAQ:AMLX) plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027 following positive late-stage trial results. During its third-quarter earnings call
Directly affected
- AMLX Amylyx Pharmaceuticals-13.3% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- LLY Eli Lilly and+19.9% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- JNJ Johnson & Johnson+1.9% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- PFE Pfizer+7.3% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- MRK Merck+5.9% 19d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| AMLX | -2.50% | -4.69% | base | -4.55% | after close | after close | after close |
| XLV | -2.96% | -2.66% | base | -1.09% | after close | after close | after close |
| XBI | -0.81% | -4.43% | base | -5.00% | after close | after close | after close |
| LLY | -3.15% | -0.45% | base | -1.48% | after close | after close | after close |
| JNJ | -0.43% | -2.09% | base | -0.20% | after close | after close | after close |
| PFE | -2.73% | -0.26% | base | -0.73% | after close | after close | after close |
| MRK | -2.69% | -1.28% | base | -0.11% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Amylyx Pharmaceuticals Q3 Earnings Call Highlights Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| AMLX | that day | -4.55% | still updating |
| AMLX | three days earlier | -4.69% | final price |
| AMLX | five days earlier | -2.50% | final price |
| JNJ | that day | -0.20% | still updating |
| JNJ | three days earlier | -2.09% | final price |
| JNJ | five days earlier | -0.43% | final price |
| LLY | that day | -1.48% | still updating |
| LLY | three days earlier | -0.45% | final price |
| LLY | five days earlier | -3.15% | final price |
| MRK | that day | -0.11% | still updating |
| MRK | three days earlier | -1.28% | final price |
| MRK | five days earlier | -2.69% | final price |
| PFE | that day | -0.73% | still updating |
| PFE | three days earlier | -0.26% | final price |
| PFE | five days earlier | -2.73% | final price |
| XBI | that day | -5.00% | still updating |
| XBI | three days earlier | -4.43% | final price |
| XBI | five days earlier | -0.81% | final price |
| XLV | that day | -1.09% | still updating |
| XLV | three days earlier | -2.66% | final price |
| XLV | five days earlier | -2.96% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 62 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 36 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 58 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 62 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 76 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 42 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 78 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “Amylyx Pharmaceuticals Q3 Earnings Call Highlights” looks
12 out of 100Price not final
“Amylyx Pharmaceuticals Q3 Earnings Call Highlights” scores 12 out of 100. The score uses 1 sources. The price is not final yet.